🇺🇸 FDA
Patent

US 11224646

Intranasal delivery of a cyclic-di-nucleotide adjuvanted vaccine for tuberculosis

granted A61KA61K2039/5256A61K2039/53

Quick answer

US patent 11224646 (Intranasal delivery of a cyclic-di-nucleotide adjuvanted vaccine for tuberculosis) held by The Regents of the University of California expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jan 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K2039/5256, A61K2039/53, A61K2039/543, A61K2039/545